Anti-Infectives · LP-023
Acyclovir Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-023Anti-Infectives
- Generic identity
- AcyclovirTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-023
- Generic identity
- Acyclovir
- Presentation
- Tablet
- Catalogue strength
- 200 mg; 400 mg; 800 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: acyclovir.
- Dosage form: tablet.
- Proposed strengths: 200 mg, 400 mg and 800 mg.
- General catalogue pack: blister 10 × 10 tablets.
Layer 02 · Unresolved product-specific fields
- Strength-to-pack/SKU mapping and exact tablet coating/score/divisibility.
- Exact excipients and whether release characteristics differ by strength.
- Approved indication, age eligibility, renal-use instructions and administration guidance for the exact product.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 200 mg | Tablet | — | Catalogue pack: blister 10 × 10 tablets; strength-specific mapping not supplied | No strength-specific SKU or divisibility claim established. |
| B | 400 mg | Tablet | — | Catalogue pack: blister 10 × 10 tablets; strength-specific mapping not supplied | No strength-specific SKU or divisibility claim established. |
| C | 800 mg | Tablet | — | Catalogue pack: blister 10 × 10 tablets; strength-specific mapping not supplied | No strength-specific SKU or divisibility claim established. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Acyclovir, also spelled aciclovir, is an antiviral used in selected herpes-virus infections. Oral tablets and skin cream differ in the infections and sites for which they are appropriate. Antiviral treatment can control an episode or support a clinician’s longer-term plan, but it does not eradicate latent herpes infection. This ingredient profile is educational and does not establish an approved Luang Pharma indication or a claim that transmission is prevented.
Clinical context and therapeutic role
The clinician considers whether disease is localized or extensive, the virus involved, timing, immune status and the appropriate route. An oral antiviral may be considered in situations where a topical product would not be sufficient. Eye involvement, severe illness, dehydration or infection in an immunocompromised person requires prompt assessment. Recurrence and prevention counseling should be individualized; symptoms and lesions can have causes other than a herpes-virus infection.
Selected safety context
Oral acyclovir can cause kidney injury, particularly in vulnerable or dehydrated patients, and neurologic effects such as confusion may occur when exposure is excessive. Kidney function and other nephrotoxic medicines deserve review. Topical cream can cause local stinging or irritation and is not an ophthalmic product. Serious allergy requires urgent help. Genital or ocular symptoms, spreading lesions or failure to improve should be assessed rather than treated indefinitely with a catalogue-listed product.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified prescriber should establish the infection and need for treatment, consult current local guidance and resistance information where relevant, and select a suitable route. Generic reference literature is not a substitute for the authorized local product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Strength/form-to-pack SKU matrix and controlled packaging artwork where more than one variant is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07b checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: AciclovirArchived source classification: public-health medicine reference | Source revision recorded: Page reviewed 23 February 2026; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-023.
Professional enquiries
Request product-specific evidence for LP-023.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.